Skip to main content

Ongoing FDAEvent 98967 (2 months ago)

SafeOp Patient Interface

The device may experience loss or interruption of triggered electromyography functionality during use.

Moderate risk

Using it may cause temporary or medically reversible health problems. Serious harm is unlikely.

FDA Class II recall · How risk is rated

What to do

What happened

Alphatec Spine, Inc., of Carlsbad, California, began a recall of the SafeOp Patient Interface, REF AIX11240, part of the SafeOp 3: Neural Informatix System, on May 13, 2026. The FDA added the recall to its Enforcement Report on July 23, 2026.

The intraoperative neuromonitoring device may, due to a software issue, experience loss or interruption of triggered electromyography (tEMG) functionality during use, displaying as system faults, loss of communication between the Patient Interface and Tablet, and prompts requiring system reboot, which may result in increased operative time and surgical plan change.

The device was distributed nationwide in the states of Texas, Missouri, and Indiana.

Summary by Recall Canary from the FDA notice.

What to do

We don't have product-specific instructions for this recall. FDA's general advice for medical device recalls:

  1. A device recall doesn't always mean you must stop using it: it may need to be checked, adjusted or fixed.
  2. Talk to your health care provider before you stop using it.

Is yours affected?

Affected if its UDI-DI matches.

  1. SafeOp Patient Interface, REF: AIX11240, part of SafeOp 3: Neural Informatix System

    UDI-DI
    • 00190376517506

Details

Company began the recall
Sold in

US Nationwide distribution in the states of Texas, Missouri, Indiana.

Event ID
98967
Recall No.
Z-2793-2026
Company
Alphatec Spine, Inc.Carlsbad, California
  1. Company began the recall

  2. Added to FDA's Enforcement Report · Classified by FDA

  3. Listed on Recall Canary

  4. In FDA's weekly enforcement report

  5. Summary updated

All recalls from Alphatec Spine, Inc.

Summary by Recall Canary, written with AI · summary updated Oct 2, 2026 · primary source: U.S. Food and Drug Administration